Literature DB >> 28985575

Research progress in modern structure of platinum complexes.

Linkui Bai1, Chuanzhu Gao2, Qinghua Liu1, Congtao Yu1, Zhuxin Zhang1, Linxiang Cai1, Bo Yang1, Yunxu Qian1, Jian Yang1, Xiali Liao1.   

Abstract

Since the antitumor activity of cisplatin was discovered in 1967 by Rosenberg, platinum-based anticancer drugs have played an important role in chemotherapy in clinic. Nevertheless, platinum anticancer drugs also have caused severe side effects and cross drug resistance which limited their applications. Therefore, a significant amount of efforts have been devoted to developing new platinum-based anticancer agents with equal or higher antitumor activity but lower toxicity. Until now, a large number of platinum-based complexes have been prepared and extensively investigated in vitro and in vivo. Among them, some platinum-based complexes revealing excellent anticancer activity showed the potential to be developed as novel type of anticancer agents. In this account, we present such platinum-based anticancer complexes which owning various types of ligands, such as, amine carrier ligands, leaving groups, reactive molecule, steric hindrance groups, non-covalently binding platinum (II) complexes, Platinum(IV) complexes and polynuclear platinum complexes. Overall, platinum-based anticancer complexes reported recently years upon modern structure are emphasized.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Antitumor agents; Carrier ligands; Cytotoxicity; Leaving groups; Platinum; Structure-activity relationship

Mesh:

Substances:

Year:  2017        PMID: 28985575     DOI: 10.1016/j.ejmech.2017.09.034

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

1.  Highly Promising Antitumor Agent of a Novel Platinum(II) Complex Bearing a Tetradentate Chelating Ligand.

Authors:  Ismail Yılmaz; Okan Remzi Akar; Merve Erkisa; Selin Selvi; Abdurrahman Şengül; Engin Ulukaya
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

Review 2.  Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Rita Santamaria; Carlo Irace
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

3.  Mono and dinuclear platinum and palladium complexes containing adamantane-azole ligands: DNA and BSA interaction and cytotoxicity.

Authors:  Ana Luiza de Andrade Querino; Jessika Thayanne da Silva; Josiane Teixeira Silva; Gustavo Miguel Alvarenga; Carolina Hahn da Silveira; Mariana Torquato Quezado de Magalhães; Otávio Augusto Chaves; Bernardo Almeida Iglesias; Renata Diniz; Heveline Silva
Journal:  J Biol Inorg Chem       Date:  2019-10-16       Impact factor: 3.358

Review 4.  Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer.

Authors:  Chengyi Mao; Xiaoxi Zeng; Chao Zhang; Yushang Yang; Xin Xiao; Siyuan Luan; Yonggang Zhang; Yong Yuan
Journal:  Front Cell Dev Biol       Date:  2021-02-11

5.  Translation inhibition and suppression of stress granules formation by cisplatin.

Authors:  Paulina Pietras; Anaïs Aulas; Marta M Fay; Marta Leśniczak-Staszak; Mateusz Sowiński; Shawn M Lyons; Witold Szaflarski; Pavel Ivanov
Journal:  Biomed Pharmacother       Date:  2021-12-01       Impact factor: 6.529

6.  Novel cis-Pt(II) Complexes with Alkylpyrazole Ligands: Synthesis, Characterization, and Unusual Mode of Anticancer Action.

Authors:  Jana Kasparkova; Hana Kostrhunova; Vojtech Novohradsky; Аlexey A Logvinov; Viktor V Temnov; Nataliya E Borisova; Tatiana A Podrugina; Lenka Markova; Pavel Starha; Alexey A Nazarov; Viktor Brabec
Journal:  Bioinorg Chem Appl       Date:  2022-03-02       Impact factor: 7.778

Review 7.  Structural modifications of berberine and their binding effects towards polymorphic deoxyribonucleic acid structures: A review.

Authors:  Lanlan Fu; Jiajia Mou; Yanru Deng; Xiaoliang Ren
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

8.  Use of Half-Generation PAMAM Dendrimers (G0.5-G3.5) with Carboxylate End-Groups to Improve the DACHPtCl2 and 5-FU Efficacy as Anticancer Drugs.

Authors:  Cláudia Camacho; Helena Tomás; João Rodrigues
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

Review 9.  The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It.

Authors:  Heather Armstrong; Michael Bording-Jorgensen; Stephanie Dijk; Eytan Wine
Journal:  Cancers (Basel)       Date:  2018-03-20       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.